• Fractyl Health released a preclinical research presentation on pancreas-targeted AAV GLP-1 gene therapy for type 2 diabetes.
• Work highlights improved beta-cell function with lower cellular stress in animal models, positioning the program as a potential one-time intervention.
• Asset RJVA-001 remains investigational, has clinical trial authorization in the Netherlands, is under review in additional EU countries and Australia.
• RJVA-001 and the Rejuva delivery device have not been assessed by the FDA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief on June 10, 2026, and is solely responsible for the information contained therein.